Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,701–10,800 of 10,906
Suria, C., Boscá-Watts, M. M., Navarro, P., Tosca-Cuquerella, J., Antón, R., Sanahuja, A., Revaliente, M., & Mínguez, M. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2021.06.003
Kafle, S., Chhetri, V., Bajracharya, J. L., Pokharel, L., Dawadi, S., Basnet, U., Dhungana, S., & Neupane, D. P. (2023) · medRxiv · doi:10.1101/2023.08.30.23294839
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0010
Moolamalla, S., Bakshi, K., & Medarametla, V. (2022) · doi:10.2196/preprints.37610
Takeuchi, R., Saito, M., Kurogi, R., Kiyama, N., Yamanishi, Y., Dodo, K., Kamatani, T., Shirasaki, Y., Tsai, C.-H., Yotsumoto, S., et al. (2025) · International Conference on Solid-State Sensors, Actuators and Microsystems · doi:10.1109/transducers61432.2025.11110425
“This mechanism involves the activation of inducible caspase 9 by a synthetic dimerizing drug, acting as the nano-artifact, leading to rapid cell death.”
Su, J., Hamway, Y., Mistretta, D., Liao, B., Ma, Z., Schluckebier, J., Xie, Z., Polezhaeva, O., Jradi, W., Braun, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1827532 · Cited by 1
Sehgal, S. A., Malik, G., Atri, R., et al. (2023) · Journal of Research in Applied and Basic Medical Sciences · doi:10.61186/rabms.9.4.200
Public Health Must Transcend Folkbiology
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0006
Marin, J., Bourgoin, P., Saverna, N., García, C. C., Lafforgue, P., Busnel, J., & Balandraud, N. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4473142
van der Pol, S., Beck, E. C., Westra, T. A., Postma, M. J., & Boersma, C. (2026) · Vaccines · doi:10.3390/vaccines14040364
“These vaccines were developed to provide strong protection against COVID-19, and their high effectiveness has been consistently demonstrated in both clinical trials [1–3] and real-world studies [4,5], including evidence from the Netherlands showing robust protection against severe outcomes [6].”
Interactions hôtes/lentivirus et contrôle de l'infection avec des vaccins LentiDNA innovants
Chergui, H. E. (2024) · theses.fr (ABES) · doi:10.70675/53cd7138z7fedz42f7zb5c3zb18ef5a33362
Roederer, A. L., Li, C. J., Lim, E. Y. P., et al. (2025) · medRxiv · doi:10.1101/2025.03.01.25323010
“The first generation of COVID vaccines 6–9 were based on the Wuhan strain of SARS-CoV-2 spike protein, containing 2 proline-stabilizing mutations that were previously used to stabilize other related spike proteins 10 .”
Determining the Rate of COVID-19 Infection in Post-Vaccinated Individuals and Its Severity
Ali, A., & Butt, A. R. (2023) · Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · doi:10.48036/apims.v18i4.673
Clinical Translation of Smart Nanomaterials
Mariappan, V., & Moorthi, P. V. (2026) · Springer eBooks · doi:10.1007/978-981-95-9386-6_15 · Cited by 1
Introduction to a review series on RNA therapeutics in hematology
Gotlib, J. R. (2023) · Blood · doi:10.1182/blood.2023020910
COVID-19 Vaccines: Development, Efficacy, Safety, and Global Distribution
Tsolmon, B. (2023) · Pacific International Journal · doi:10.55014/pij.v6i1.363
Ber, I., Na’amnih, W., Perlman, S., Kasstan, B., Lerman, Y., & Muhsen, K. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2429233 · Cited by 2
Bürzle, O., Menges, D., Maier, J. D., et al. (2022) · medRxiv · doi:10.1101/2022.09.27.22280403
Cieślak, I., Kwapisz, M., Tronina, O., Gotlib, J., Lisik, W., Wasiak, D., Hreńczuk, M. K., Rahnama, M., & Małkowski, P. (2022) · Annals of Transplantation · doi:10.12659/aot.936949
Healthcare workers' Attitude and Knowledge Towards the Safety of Nucleotide-Based Vaccines.Preprint
Madadha, M. E. A., Ahmed, K., Rayyan, R., Ahram, M. A., Al-Sanouri, N., Demour, S. A., & Ahmad, M. M. (2021) · Research Square · doi:10.21203/rs.3.rs-744975/v1
COVID ‐19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey
Li, Y., Muppidi, S., Unnithan, S., Al‐Khalidi, H. R., Masterson, S., Huff, W., Juel, V. C., Guptill, J. T., & Raja, S. M. (2025) · Muscle & Nerve · doi:10.1002/mus.28466
“The frequency of participant-reported vaccine side effects was comparable to those observed in the clinical trials that supported vaccine regulatory approval (Table S3) [12–14].”
Adverse Events of COVID-19 Vaccine in Japanese University Students
Otaka, Y., TAJIMA, K., Kimura, Y., Itoh, N., Kanai, K., & Ueno, S. (2023) · Journal of Veterinary Epidemiology · doi:10.2743/jve.27.39
Signal detection of COVID ‐19 vaccines adverse events using spontaneous reports from South Korea
Jeong, H. S., & Chun, B. C. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5629 · Cited by 1
Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study
Choi, Y., Jacobs, D. R., Kramer, H. J., Coresh, J., Cushman, M., Reiner, A. P., Demmer, R. T., Tracy, R. P., Sun, Y., Balte, P., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.011 · Cited by 1
Park, S., Kim, S., Kim, S., Shin, K.-S., Kang, C., Hong, E., Im, W., Jeong, J., Yu, W., Ko, K., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117503
FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval
Monawwer, S. A., & Naeem, R. (2021) · Journal of Global Health Economics and Policy · doi:10.52872/001c.30733
COVID-19 Vaccines and their Potential use in Patients with Hematological Malignancies
Dada, A. M., Albishi, G. E., & Usman, B. (2021) · Journal of Applied Hematology · doi:10.4103/joah.joah_28_21
Hannawi, S., Villalobos, R. E., Burhan, E., Borra, M. D. L., Gupta, R. K., Aquitania, G. P., Ang, B. W., Zabat, G. M. A., Camilo C. Roa, Jr., Jesus, L. Z. D., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4689124
Golemi‐Kotra, D., & Wu, J. (2021) · doi:10.64628/aam.tgwps3qh9
Cationic polymer-based nanoparticles in cancer vaccines
Shi, X., Dong, Y., Gao, Y., & Guo, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95513-3.00022-8
Development of a virus particle fusion assay to study and target virus entry
Terzopoulos, N., Tiplady, O., Pan, Q., & Liang, C. (2026) · Virology · doi:10.1016/j.virol.2026.111025
Pestoni, G., Menges, D., Fenwick, C. D., Scheuchzer, P., Braun, J., Haile, S. R., Ballouz, T., Zeder, C., Stoffel, N. U., Zimmermann, M. B., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1764884
Mostafa, H. H., & Pinsky, B. A. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0093
Challenges of COVID-19 Vaccination in the Context of Transplantation - A Narrative Review
Meshram, H. S., Kute, V. B., Agarwal, S. K., & Sahay, M. (2021) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_52_21
Behcet's disease-related panuveitis following COVID-19 vaccination: A case report
Lin, R.-T., Liu, P., Chang, C.-W., Cheng, K., Chen, K., & Chang, Y. (2024) · World Journal of Radiology · doi:10.4329/wjr.v16.i9.460
Trust decay in the American healthcare delivery system
Dawson, D. A. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.20.2.0318
Wang, J., Ni, S., Chen, Q., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4758354
Feuchtenberger, M., Kovacs, M. S., Eder, A., Nigg, A. P., Almanzar, G., Prelog, M., & Schäfer, A. (2024) · Rheumatology Advances in Practice · doi:10.1093/rap/rkae111
Singh, A., Gurada, N. C., Mahendru, N., Kashyap, A., Bhanu, S., Sharma, N., & Kaushik, R. (2024) · International Journal of Clinical Biochemistry and Research · doi:10.18231/j.ijcbr.2023.057
mRNA therapy: A novel approach for retinal neurodegenerative diseases
Zhang, B., Tang, J., Zhang, Q., Qiu, Y., Cheng, Y., Yu, S., Liu, L., Xue, J., Liu, X., He, Q., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01306 · Cited by 3
Fucà, G., Lecchi, M., Ciniselli, C. M., Ottini, A., Spagnoletti, A., Mazzeo, L., Morelli, D., Frati, P., Stroscia, M., Ebrahem, E., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221108687
Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
Tian, J., Tran, K. T. M., Pogostin, B. H., Sheridan, O., Mursalova, S., Lee, A. H., Liu, S., Hamkins, J., Antov, D., Power, A. L., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03331-w · Cited by 2
Jin, Z., Wu, J., Huang, T., Zhao, K., Zhang, M., Liu, J., Song, J., Yin, H. H., Wu, X., Liu, J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12053-4
“Both the low-dose ( P < 0.001) and high-dose Adverse event description Severity [6] Low-dose vaccine group ( N = 50)”
InfluentialA Theoretical and Statistical Comparison of Major COVID-19 Vaccines
Iyer, K. (2024) · Journal of Student Research · doi:10.47611/jsr.v13i1.2440
Pandey, B., Wang, Z., Jimenez, A. C., Bhatia, E., Jain, R., Beach, A., Maniar, D., Hosten, J., O’Farrell, L., Vantucci, C. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.05.539395
Strickler, S. S., Esper, A. M., Wells, L., Wood, A. R., Frediani, J. K., Nehl, E. J., Waggoner, J. J., Rebolledo, P. A., Levy, J. M., Figueroa, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1031083
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959.1 · Cited by 1
COVID-19 immunization in people with cancer—Is it safe and efficient? What do we know?
Lazăr, D. E., & Munteanu, A. (2022) · Tumori Journal · doi:10.1177/03008916221090544
Rao, S. (2026) · INNOVAPATH · doi:10.63501/w1mrve44
“Two large randomized trials subsequently reported efficacy against symptomatic COVID-19 of approximately 95 percent for BNT162b2 and 94 percent for mRNA-1273 (Baden et”
Huskić, I. M., Benšić, M., Kretonić, K., Miškulin, I., Miškulin, M., Milas, J., & Nujić, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127440
Bhatt, U., Hérate, C., Estelien, R., Relouzat, F., Dereuddre‐Bosquet, N., Maciorowski, D., Diop, C., Couto, E., Staiti, J., Cavarelli, M., et al. (2024) · Vaccines · doi:10.3390/vaccines12080882
Moon, S. M., An, J. N., Kwon, J. H., Kim, S. G., & Kim, H. W. (2025) · Microorganisms · doi:10.3390/microorganisms13102362
“Heterologous prime-boost vaccination strategies have emerged as a critical approach for COVID-19 immunization, particularly driven by vaccine supply constraints and the need to optimize immune responses against emerging variants [19,20].”
Lundstrom, K. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89837-9.00014-0
Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccinePreprint
Carnell, G., Vendramelli, R., Whittaker, C., Holbrook, J. A., Parthasarathy, S., Stewart, H., Olivier, J., Warner, B. M., Truong, T., George, C. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.17.25338244
Auroux, M., Laurent, B., Coste, B., Massy, E., Mercier, A., Durieu, I., Confavreux, C. B., Lega, J., Mainbourg, S., & Coury, F. (2022) · Revue du Rhumatisme · doi:10.1016/j.rhum.2022.07.002
Kugeler, K. J., Williamson, J., Curns, A. T., Healy, J. M., Nolen, L. D., Clark, T. A., Martin, S. W., & Fischer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264179
Blake, I., Singleton, R. J., Bruden, D. J. T., Gray, J., Fischer, M., & Keck, J. W. (2026) · International Journal of Circumpolar Health · doi:10.1080/22423982.2026.2706888
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults
Liu, S. T. H., González‐Domínguez, I., Martínez-Pérez, A., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128870
Psoriasiform Dermatitis Associated With the Moderna COVID-19 Messenger RNA Vaccine
Daneshbod (2022) · Cutis · doi:10.12788/cutis.0656
NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in AdolescentsPreprint
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4669162
Self-citationIkrar, T., Muchsin, W., & Sophian, A. (2026) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.70143
Cumplido, D. R., Ordóñez, P., Rius, R. L., Videla, S., Otero, A., Carnaval, T., Poltorak, V., Moya-Guerola, M., Aumatell, C. M., Rodriguez, S., et al. (2022) · Medicine · doi:10.1097/md.0000000000030976
Evaluation of the Knowledge and Attitude of COVID-19 Vaccines Among Pilgrims
Ahmed, O. B., Asghar, A. H., Bamaga, M. A., Bahwerth, F. S., Hariri, S. H., & Ibrahim, M. E. (2023) · Archives of Pharmacy Practice · doi:10.51847/voxl2qreke
Zeng, Q., Yang, X. Y., Gao, Q., Lin, B., Li, Y., Huang, G., & Xu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.05.490815
Niazi, S. K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080941
“The coronavirus disease 2019 (COVID-19) vaccines, tozinameran (Comirnaty) and elasomeran (Spikevax), effectively addressed these issues, thereby enabling their development as vaccines and, in the process, facilitating the administration of billions of doses globally [3–5].”
Espinar, A. L., Ru, E. C. L., Smith, K., & Darby, B. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728751
Functionalized Nanomaterials for Drug Delivery
George, N., Janiyani, K., Ogoe, M., Gupta, A., Safo, K. K., Singh, H., & Pandya, S. R. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_3 · Cited by 2
Chang, A., Jeng, Y., Ho, C., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2917943/v1
Tramboo, M. R., Farhana, A., Zahoor, D., Iqbal, I., & Mohuiddin, Z. (2024) · Motaleat-e Tatbiqi-e Honar · doi:10.61186/jommid.12.2.100
Κοντοπούλου, Κ., Nakas, C. T., Tsekoura, M., Tsorbatzoglou, M., & Papazisis, G. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.02784
Ricke, D. O. (2023) · Journal of Modern Biology and Drug Discovery · doi:10.53964/jmbdd.2023001
Shen, C., Lin, Y.-P., Chen, W., Cheng, M.-H., Hong, J.-J., Hu, S.-Y., Shen, C., & Cheng, C. (2024) · Vaccines · doi:10.3390/vaccines12060658
Etiological Profile of Epistaxis: Pre-Pandemic Versus Pandemic.
Vlăescu, A. N., Ionita, E., Anghelina, F., Mogoanta, C. A., Ciolofan, S.-M., Rusescu, A., Ioniță, I.-G., Voiosu, C., & Hainăroșie, R. (2023) · PubMed Central · doi:10.12865/chsj.49.03.08 · Cited by 1
Stratégie vaccinale contre la Covid-19 au long terme : contrôle ou élimination ?
Mueller, J. E. (2021) · Actualité et dossier en santé publique · doi:10.3917/aedesp.114.0005
Shioda, T. (2026) · Springer eBooks · doi:10.1007/978-981-95-6378-4_2
Bhat, R., & Shanbhag, P. (2023) · Journal of Community Pharmacy Practice · doi:10.55529/jcpp.35.38.46
Fine-scale structural information substantially improves mRNA therapeutic stability prediction
Yi, S., Ali, S. E., Jadeja, Y., Davis, J. W., & Metkar, M. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102960 · Cited by 2
“Although the rapid mRNA-based vaccine development has highlighted the platform’s potential, 1 mRNA instability remains a critical barrier to broader deployment, particularly in settings lacking reliable cold-chain infrastructure such as developing countries.”
Uozumi, R. (2023) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.54.2_89
The World ChangedTHE COVID‐19 PANDEMIC
(2022) · Wiley eBooks · doi:10.1002/9781683673828.ch10
Enhancing RNA Delivery: Practical insights into NeoLNPTM transfection reagent
Chen, X., Wu, Y. X., Liu, L., & Wang, W. (2025) · Methods · doi:10.1016/j.ymeth.2025.05.007
Wieske, L., Kummer, L. Y. L., van Dam, K. P. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19298171
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628929
Additional file 1 of Landscape and selection of vaccine epitopes in SARS-CoV-2
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W. A., Garness, J. A., Entwistle, S., Willis, C., Vensko, S. P., II, Woods, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14782768
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17359033
Starrfelt, J., Danielsen, A. S., Buanes, E. A., Juvet, L. K., Lyngstad, T. M., Rø, G., Veneti, L., Watle, S. V., & Meijerink, H. (2022) · Figshare · doi:10.6084/m9.figshare.20786762
Duarte, M. B. O., Leal, F., Argenton, J. L. P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17083862
Mair, M. J., Maj-Hes, A., Nussbaumer-Pröll, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568304
Lakhlifi, C., Lejeune, F., Rouault, M., Khamassi, M., & Rohaut, B. (2024) · Figshare · doi:10.6084/m9.figshare.26583951
Takahashi, K., Samura, O., Hasegawa, A., Okubo, H., Morimoto, K., Horiya, M., Okamoto, A., Ochiai, D., Tanaka, M., Sekiguchi, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22792785
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628926
Almeda, N., Díaz-Milanés, D., Guiterrez-Colosia, M. R., & GARCÍA-ALONSO, C. R. (2022) · Figshare · doi:10.6084/m9.figshare.21174243
Filippini, F., Giacomelli, M., Bazzani, C., Fredi, M., Semeraro, P., Tomasi, C., Franceschini, F., Caruso, A., Cavazzana, I., & Giagulli, C. (2024) · Figshare · doi:10.6084/m9.figshare.26597237
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.